060C8F0B-DAB8-43DB-80C9-3404AFCC0B7D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 75.19710906701708
- age_years
- 37
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.557
- E2F_TARGETS+0.529
- MYC_TARGETS_V2+0.486
- OXIDATIVE_PHOSPHORYLATION+0.467
- DNA_REPAIR+0.464
- G2M_CHECKPOINT+0.431
- ALLOGRAFT_REJECTION+0.373
- INTERFERON_ALPHA_RESPONSE+0.343
- PANCREAS_BETA_CELLS+0.318
- INTERFERON_GAMMA_RESPONSE+0.290
Top 10 suppressed
- UV_RESPONSE_DN-0.310
- KRAS_SIGNALING_DN-0.193
- ESTROGEN_RESPONSE_EARLY-0.167
- HEDGEHOG_SIGNALING-0.160
- TGF_BETA_SIGNALING-0.156
- MYOGENESIS-0.152
- PI3K_AKT_MTOR_SIGNALING-0.151
- BILE_ACID_METABOLISM-0.139
- HEME_METABOLISM-0.136
- MITOTIC_SPINDLE-0.127
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.911 |
| 2 | 4F09B010-97EC-4792-BF5A-42E9EF55894D | — | — | 0.902 |
| 3 | E92DD0CC-DD0F-469D-8357-228A4A67DBD6 | — | — | 0.901 |
| 4 | 381221D6-D0E6-47B3-AB59-468AE2A5FC0A | — | — | 0.892 |
| 5 | 2E401C42-010F-4AFC-A362-B69426418626 | — | — | 0.876 |
| 6 | TCGA-CV-5966-01A-11R-1686-07 | — | — | 0.872 |
| 7 | E24D233D-71BD-4EC2-A671-375917F24E5C | — | — | 0.870 |
| 8 | E7BE221B-273D-4C04-BE79-366E6455EFBC | — | — | 0.868 |
| 9 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.867 |
| 10 | 77907EB2-E529-4633-A580-C6DD7993A704 | — | — | 0.865 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.557 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.529 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.486 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.467 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.464 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.431 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.373 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.343 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.318 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.286 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.273 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.244 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.236 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.232 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.228 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.226 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.207 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.207 | Inavolisib | — uncovered |